Unknown

Dataset Information

0

Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study.


ABSTRACT: Background:There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin that will determine whether 5 years of daily 100-mg enteric-coated aspirin extends disability-free and dementia-free life in a healthy elderly population and whether these benefits outweigh the risks. Methods:Set in primary care, this randomized double-blind placebo-controlled trial has a composite primary endpoint of death, incident dementia or persistent physical disability. Participants aged 70+ years (non-minorities) or 65+ years (U.S. minorities) were free of cardiovascular disease, dementia, or physical disability and without a contraindication to, or indication for, aspirin. Baseline data include physical and lifestyle, personal and family medical history, hemoglobin, fasting glucose, creatinine, lipid panel, urinary albumin:creatinine ratio, cognition (3MS, HVLT-R, COWAT, SDMT), mood (CES-D-10), physical function (gait speed, grip strength), Katz activities of daily living and quality of life (SF-12). Results:Recruitment ended in December 2014 with 16,703 Australian and 2,411 U.S. participants, a median age of 74 (range 65-98) years and 56% women. Approximately 55% of the U.S. cohort were from minority groups; 9% of the total cohort. Proportions with hypertension, overweight, and chronic kidney disease were similar to age-matched populations from both countries although lower percentages had diabetes, dyslipidemia, and osteoarthritis. Discussion:Findings from ASPREE will be generalizable to a healthier older population in both countries and will assess whether the broad benefits of daily low-dose aspirin in prolonging independent life outweigh the risks.

SUBMITTER: McNeil JJ 

PROVIDER: S-EPMC5861878 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin that will determine whether 5 years of daily 100-mg enteric-coated aspirin extends disability-free and dementia-free life in a healthy elderly population and whether these benefits outweigh the risks.<h4>Methods</h4>Set in primary care, this randomized double-blind placebo-cont  ...[more]

Similar Datasets

| S-EPMC7658662 | biostudies-literature
| S-EPMC6924574 | biostudies-literature
| S-EPMC6456041 | biostudies-literature
| S-EPMC6022241 | biostudies-literature
| S-EPMC7957955 | biostudies-literature
| S-EPMC6380180 | biostudies-literature
| S-EPMC6812602 | biostudies-literature
| S-EPMC7177891 | biostudies-literature
| S-EPMC4576996 | biostudies-literature
| S-EPMC7957958 | biostudies-literature